About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 536 record(s)
Req # A-2022-001451
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-075406-962.Organization: Health Canada
May 2023
Req # A-2022-001453
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-111972-42.Organization: Health Canada
May 2023
Req # A-2022-001460
Adverse Drug Reactions (ADRs). Report numbers: 000987016, 000987017, 000987019, 000987020, E2B_05094781, E2B_05100054, E2B_05100069, E2B_05272772, 000987022, 000987025.Organization: Health Canada
May 2023
Req # A-2022-001463
Adverse Drug Reaction (ADR) for DOXYLAMINE SUCCINATE / PYRIDOXINE HYDROCHLORIDE. Report number: E2B_05933342.Organization: Health Canada
May 2023
Req # A-2022-001467
Adverse Drug Reactions (ADRs). Report numbers: E2B_05933105, 001016349, E2B_05917203, E2B_05925115, 001016201, E2B_05886658, E2B_05884649, 001016116, E2B_05949583, E2B_05955018.Organization: Health Canada
May 2023
Req # A-2022-001468
Adverse Drug Reactions (ADRs). Report numbers: 001017761, E2B_05934321, E2B_05923043, E2B_05916486, 001016253, E2B_05880850, E2B_05959630, E2B_05897976, 001017946 E2B_05881222.Organization: Health Canada
May 2023
Req # A-2022-001473
Adverse Drug Reactions (ADRs) for PATIROMER. Report numbers: E2B_05928753, E2B_05929411, E2B_05937963. ADRs for SUCROFERRIC OXYHYDROXIDE. Report numbers: E2B_05897175, E2B_06025390. ADR for REXULTI. Report number: E2B_05885061. ADR for REXULTI AND…Organization: Health Canada
May 2023
Req # A-2022-001474
Adverse Drug Reactions (ADRs) for ABILIFY MAINTENA. Report numbers: 001016212, E2B_05937468, E2B_05969422. ADRs for ABILIFY MAINTENA AND ARIPIPRAZOLE. Report numbers: E2B_05883463, E2B_05905647. ADRs for ABILIFY AND ARIPIPRAZOLE. Report numbers:…Organization: Health Canada
May 2023
Req # A-2022-001490
Adverse Drug Reactions (ADRs) for PREVMYIS. Report numbers: 000731335, E2B_02849440, E2B_03009833, E2B_02754235. ADRs for PROQUAD. Report numbers: E2B_03276676, E2B_03269645, 000912797. ADRs for RECOMBIVAX HB. Report numbers: E2B_02198873,…Organization: Health Canada
May 2023
Req # A-2022-001495
Adverse Drug Reactions (ADRs). Report numbers: E2B_05172969, E2B_05223762, 001001275, E2B_05627878, E2B_05766145, E2B_05797168, E2B_04659086, E2B_04737772, 000998122, E2B_05422984.Organization: Health Canada
May 2023